Drug Developers Want a Bailout, Too

Recs

6

Disney Buys Marvel!

...And David Gardner called it. He's up 1,334%! See what David's recommending that you buy NEXT!

Click here now to find out!

Need a sign of how bad the economy's looking? Now, companies from perhaps the most recession-resistant industry -- health care -- want a government bailout of their own.

Drug developers apparently figured that if automakers like General Motors, homebuilders like Toll Brothers, and financial companies like Bank of America (NYSE: BAC) were all asking for bailouts ... they might as well stick their hands out, too. The industry's trade group, the Biotechnology Industry Organization (BIO), headed to Washington yesterday to ask for a handout for drug companies in the next stimulus package.

The bailout won't help profitable companies like Pfizer (NYSE: PFE), Biogen Idec (Nasdaq: BIIB), or Amgen (Nasdaq: AMGN). Instead the proposal is designed to lend a hand to small drug developers like Exelixis (Nasdaq: EXEL) and Seattle Genetics. Cash-strapped companies want up-front cash from the government now, in exchange for the net operating loss (NOL) credits that they would normally be able to use once they become profitable.

To make the proposal a little more palatable to the government, the exchange wouldn't be one-for-one; since plenty of drugmakers never become profitable, lots of NOLs go unused. Should the legislation go through, it'll be interesting to see whether companies on the verge of profitability, like Elan or Amylin Pharmaceuticals (Nasdaq: AMLN), forgo the initial cash to take the full credit down the road.

As an investor in drug developers, I feel conflicted about this. On one hand, the government already gives companies a research tax credit, and this new request seems like less of a handout than that. On the other hand, since when did capitalism stop applying to whole swaths of the market? With share prices in shambles, Johnson & Johnson (NYSE: JNJ) has been shrewdly adding to its suite of companies. And several other large pharma companies have the cash to either purchase their tinier brethren outright, or invest in their drug-development programs.

As a taxpayer, I wonder where and when the bailout mania will end. Next thing you know, the government will be handing out subsidies to oil companies to compensate for $50-a-barrel crude, and subsidizing beer drinkers because Homer Simpson asked them to.

More bailout Foolishness:

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Pfizer is a pick of the Income Investor and Inside Value newsletters. Johnson & Johnson and Bank of America are also  Inside Value picks. Exelixis is a Rule Breakers recommendation. Biogen Idec is a Stock Advisor selection. The Fool owns shares of Pfizer and Exelixis. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy. Mmm... disclosure. *drooling sound*

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 11, 2008, at 3:25 PM, MotleyTom2U wrote:

    After 14 years, I'm being laid off by one of those drug development companies. Maybe I should get in line for a bailout, too! Sheesh!!

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 793015, ~/Articles/ArticleHandler.aspx, 11/9/2009 11:27:37 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:00 PM
BIIB $45.41 Down -0.35 -0.76%
Biogen Idec, Inc. CAPS Rating: ****
BAC $15.77 Up +0.72 +4.78%
Bank of America Co… CAPS Rating: ***
JNJ $60.75 Up +0.45 +0.75%
Johnson & Johnson CAPS Rating: *****
EXEL $7.05 Up +0.25 +3.68%
Exelixis, Inc. CAPS Rating: *****
PFE $17.43 Up +0.47 +2.77%
Pfizer, Inc. CAPS Rating: ****
AMLN $12.30 Up +0.23 +1.91%
Amylin Pharmaceuti… CAPS Rating: ****
AMGN $54.91 Up +0.22 +0.40%
Amgen, Inc. CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Variable cost: A variable cost is an expense that rises or falls in conjunction with a company's level of productivity.

Want to learn more or edit this definition?
Click here to read more!